{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:31:25Z","timestamp":1762673485222},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,7,5]],"date-time":"2005-07-05T00:00:00Z","timestamp":1120521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,7,5]],"date-time":"2005-07-05T00:00:00Z","timestamp":1120521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1038\/sj.pcan.4500815","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T20:50:08Z","timestamp":1120683008000},"page":"253-259","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms"],"prefix":"10.1038","volume":"8","author":[{"given":"J E","family":"Quinn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L G","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E T","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R L","family":"Vessella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,7,5]]},"reference":[{"key":"BF4500815_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","volume":"68","author":"NW Clarke","year":"1991","unstructured":"Clarke NW, McClure J, George NJR . Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74\u201380.","journal-title":"Br J Urol"},{"key":"BF4500815_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jnci\/94.1.17","volume":"94","author":"JA Nemeth","year":"2002","unstructured":"Nemeth JA et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"BF4500815_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235\u20131244.","journal-title":"J Clin Invest"},{"key":"BF4500815_CR4","first-page":"295","volume":"9","author":"E Corey","year":"2003","unstructured":"Corey E et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295\u2013306.","journal-title":"Clin Cancer Res"},{"key":"BF4500815_CR5","first-page":"2602","volume":"61","author":"MV Lee","year":"2001","unstructured":"Lee MV et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602\u20132608.","journal-title":"Cancer Res"},{"key":"BF4500815_CR6","first-page":"5564","volume":"62","author":"YP Lee","year":"2002","unstructured":"Lee YP et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002; 62: 5564\u20135570.","journal-title":"Cancer Res"},{"key":"BF4500815_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357\u2013363.","journal-title":"N Engl J Med"},{"key":"BF4500815_CR8","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T et al. Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559\u20134567.","journal-title":"Clin Cancer Res"},{"key":"BF4500815_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558\u2013567.","journal-title":"J Clin Oncol"},{"key":"BF4500815_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0093-7754(01)90264-7","volume":"28","author":"H Fleisch","year":"2001","unstructured":"Fleisch H . Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. Semin Oncol 2001; 28: 45\u201347.","journal-title":"Semin Oncol"},{"key":"BF4500815_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G van der Pluijm","year":"1996","unstructured":"van der Pluijm G et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698\u2013705.","journal-title":"J Clin Invest"},{"key":"BF4500815_CR12","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1359\/jbmr.2001.16.11.2027","volume":"16","author":"O Peyruchaud","year":"2001","unstructured":"Peyruchaud O et al. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001; 16: 2027\u20132034.","journal-title":"J Bone Miner Res"},{"key":"BF4500815_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0093-7754(01)90263-5","volume":"28","author":"GR Mundy","year":"2001","unstructured":"Mundy GR, Yoneda T, Hiraga T . Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001; 28: 35\u201344.","journal-title":"Semin Oncol"},{"key":"BF4500815_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309\u2013319.","journal-title":"Cell"},{"key":"BF4500815_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260\u20131268.","journal-title":"Genes Dev"},{"key":"BF4500815_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","volume":"247","author":"A Mizuno","year":"1998","unstructured":"Mizuno A et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610\u2013615.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF4500815_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s001090100226","volume":"79","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Heufelder AE . Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243\u2013253.","journal-title":"J Mol Med"},{"key":"BF4500815_CR18","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432\u20134436.","journal-title":"Cancer Res"},{"key":"BF4500815_CR19","first-page":"2096","volume":"63","author":"H Yonou","year":"2003","unstructured":"Yonou H et al. Osteoprotegerin\/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic\/severe combined immunodeficient mice. Cancer Res 2003; 63: 2096\u20132102.","journal-title":"Cancer Res"},{"key":"BF4500815_CR20","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1359\/jbmr.1999.14.9.1478","volume":"14","author":"S Morony","year":"1999","unstructured":"Morony S et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 1999; 14: 1478\u20131485.","journal-title":"J Bone Miner Res"},{"key":"BF4500815_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pros.10091","volume":"52","author":"E Corey","year":"2002","unstructured":"Corey E et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002; 52: 20\u201333.","journal-title":"Prostate"},{"key":"BF4500815_CR22","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1359\/jbmr.2003.18.10.1882","volume":"18","author":"J Pfitzenmaier","year":"2003","unstructured":"Pfitzenmaier J et al. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 2003; 18: 1882\u20131888.","journal-title":"J Bone Miner Res"},{"key":"BF4500815_CR23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1172\/JCI115539","volume":"88","author":"M Sato","year":"1991","unstructured":"Sato M et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095\u20132105.","journal-title":"J Clin Invest"},{"key":"BF4500815_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","volume":"19","author":"B Pan","year":"2004","unstructured":"Pan B et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004; 19: 147\u2013154.","journal-title":"J Bone Miner Res"},{"key":"BF4500815_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","volume":"291","author":"V Viereck","year":"2002","unstructured":"Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002; 291: 680\u2013686.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF4500815_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10585-004-2869-0","volume":"21","author":"JA Kiefer","year":"2004","unstructured":"Kiefer JA et al. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clin Exp Metastasis 2004; 21: 381\u2013387.","journal-title":"Clin Exp Metastasis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/4500815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500815","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/4500815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:58:17Z","timestamp":1648681097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/4500815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9,1]]}},"alternative-id":["BF4500815"],"URL":"https:\/\/doi.org\/10.1038\/sj.pcan.4500815","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,5]]},"assertion":[{"value":"17 February 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}